OCGN
Ocugen, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-45.44
P/S
131.52
EV/EBITDA
-9.83
DCF Value
$-0.18
FCF Yield
-9.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-1425.7%
Net Margin
-1537.4%
ROE
-2626.4%
ROA
-153.2%
ROIC
-269.4%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $-193.0K | $-17.7M | $-0.06 |
| FY 2025 | $4.4M | $-67.8M | $-0.23 |
| Q3 2025 | $1.8M | $-20.1M | $-0.07 |
| Q2 2025 | $1.4M | $-14.7M | $-0.05 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
2.81
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.